Catalio Capital Management

Also known as: Camden Partners Nexus, Nexus, Catalio Capital Management, LP

Data updated June 29, 2026

New York City, New York, United States

Catalio Capital Management is a New York-based healthcare investment firm that invests across private, public, and credit markets. Its public materials emphasize innovative healthcare companies across the company lifecycle, with a strong orientation toward biomedical technology.

Catalio belongs in the psychedelic ecosystem as a healthcare-specialist investor with atai-related investments and a historical COMPASS Pathways connection through Camden Partners Nexus. It should be read as a life-science investor with repeated source-backed sector exposure, not as a dedicated psychedelic fund.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Multi-Stage. Public focus areas include Drug Development, Clinical Infrastructure, and Digital Therapeutics & Platforms.

Public Portfolio Examples

atai Life SciencesSeries C - $125 million - Nov 23, 2020
COMPASS PathwaysSeries B - $80m - Apr 27, 2020

COMPASS Pathways named Camden Partners Nexus in 2020, and Catalio later stated that it spun out from Camden and had previously been known as Nexus. The current Catalio record therefore keeps Camden Partners Nexus and Nexus as aliases while linking the portfolio evidence to the active investment platform.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

Multi-Stage

Investment Focus Areas

Drug DevelopmentClinical InfrastructureDigital Therapeutics & Platforms